Pilot Aims To Help Manufacturers Measure Quality Culture
Executive Summary
Parenteral Drug Association is testing a program that links behaviors that cannot be measured to quality attributes that can be evaluated. Despite the US FDA’s move to drop quality culture as a metric in a recent guidance, pharma manufacturers are urged to evaluate it anyway to help avoid compliance failures.
You may also be interested in...
FDA’s Revised Quality Metrics Program: Voluntary Now, Mandatory Later
US FDA will establish mandatory quality metrics reporting through a formal rulemaking process that could take years. Meanwhile, a revised draft guidance lays out plans for voluntary quality metrics reporting that could begin by January 2018.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.